Lumos Diagnostics

?? Stockhead Last week was World Antibiotic Resistance Awareness Week - an opportunity to improve education and awareness of antimicrobial resistance (#AMR). #Lumos was featured in Stockhead as a one of several companies on the ASX actively working to combat the global rise of AMR, with its point-of-care rapid test, FebriDx. Here's an excerpt: "?????? ???????????????????? ???????????????? ???????????????? ?????? ?????????????????????? ?????????????????? (??????????), ?????????? ???? ???????? ???? ?????? ???? ???????????????????? ???? ???????????? ?????? ?????????? ????????????????’ ???????????????????????????? ?????? ?????????????????? ???????????????????????? ?????? ????????????????, ???????????????? ?????????????? ?????????? ???????????? ????$3?? ???? ?????????????????? ??????????????.???????? ?????????????? ???? ???????? ???? ?? ??????????????????-?????????? ???????? ?????????? ???????? ???????? ????$8?? ???? ?????????????? ?????? ???????? ?????????? ???? ???????????????? ?????????????????????? ?????? ??????????????.???????? ???????? ???????? ???????? ?????????????????? ?????? ?????????? ???????? ?????????? ?????????????????????? ???????????? ?????? ???? ?????? ??????-?????????????? ???????????? ?????? ?????????? ???? ?????? ????????????." Check it out ?? https://lnkd.in/gwcTq7QX $LDX #LDX #Lumos #AMR #rapidtest #pointofcare #diagnostics

?? Nine News Coverage Lumos' FebriDx? was featured on Channel Nine News during its prime time 6pm national bulletin last night, sharing insight into how this rapid diagnostic test may help healthcare professionals make informed decisions about antibiotic prescribing on the frontline. Our Non-Executive Chair, Sam Lanyon, was interviewed alongside CSIRO’s Minimising AMR Mission Lead, Professor Branwen Morgan, and Infectious Disease Expert, Professor Paul Griffin. At the heart of the story, was the lived experience of a mother-of-two, Nellie Harrison, and her three-year-old son Freddie who is navigating persistent respiratory illness. This coverage coincides with World Health Organization’s World AMR Awareness Week (WAAW), bringing timely attention to the global challenge of antimicrobial resistance, which claims over 1.2 million lives annually. Thank you to Channel 9 News reporter Meg Sydes for highlighting this important issue, and showcasing how Lumos is playing an active role in combating antibiotic resistance – both locally, and globally. Take a look ?? https://lnkd.in/g5hDiyFD $LDX #LDX #Lumos #antibioticresistance #diagnostics #innovation #rapidtest #healthcare #medicaldevice #patientcare #antimicrobialstewardship #AMR

?? World Antimicrobial Resistance Awareness Week (18-24 November) highlights one of healthcare's most pressing challenges. Lumos Diagnostics is at the forefront of addressing antimicrobial resistance (AMR) through our advanced diagnostic solutions. FebriDx?, our rapid point-of-care diagnostic test, enables healthcare professionals to distinguish between bacterial infections and non-bacterial etiology, supporting informed decisions about antibiotic prescriptions. Antimicrobial stewardship is a shared responsibility. Every individual can play a crucial role by understanding when antibiotics are necessary, following prescription guidelines carefully, and avoiding the use of unnecessary antibiotics. These simple yet powerful actions help preserve these vital medicines for generations to come. $LDX #LDX #Lumos #innovation #diagnostics #pointofcare #AMR #antimicrobialresistance #WAAW

?? Quarterly Report Lumos Diagnostics has today released its Quarterly Report & 4C for the period ending 30 September 2024. Key highlights from the Quarter include: ?? Unaudited revenue of US$3.4 million for the quarter, up 209% compared to the prior corresponding period (pcp) (Q1 FY24 - US$1.1 million). ?? Product revenue was up 200% over Q1 last year and Services revenue was up 210% on the pcp. ?? Successfully completed A$10.0 million capital raise, strongly supported by new and existing shareholders, Tenmile and Ryder Capital. ?? Cash balance of US$5.7 million as at 30 September 2024, prior to receipt of Retail Offer Proceeds of A$6.9 million. ?? Operating cash outflow of US$2.6 million, including cash receipts of US$1.2 million with the next Hologic milestone payment expected in Q2. ?? New and expanded FebriDx distributor agreements with leading distributors, Henry Schein and Thermo Fisher? Post reporting date signed partnership agreement with BARDA for US$3.0 million in non-dilutive funding to support FebriDx CLIA waiver trial in the US, with funding options to expand to US$8.3 million. Lumos CEO, Doug Ward noted: “With a strong pipeline of projects and partnerships and balance sheet strength, supported by the recent capital raise, we are well-positioned for continued growth and success.” Read the ASX release ?? https://lnkd.in/gbqiT_YV $LDX #LDX #Lumos #diagnostics #pointofcare #medtech #healthcare #innovation

?? Capital Raise Complete ?? Lumos Diagnostics has announced that it has successfully completed the retail component of its Entitlement Offer, which raised approximately A$6.9 million. The institutional component of the Entitlement Offer successfully completed last month raised approximately A$3.1 million, bringing the total amount raised under the Entitlement Offer to A$10.0 million. Lumos CEO and Managing Director, Doug Ward said, “We appreciate the strong backing from all those investors who participated in this capital raise, particularly Tenmile and Ryder Capital, who are aligned with our vision to address unmet needs in human health. These funds provide Lumos with solid backing to drive the growth of our business.” Read the ASX release ?? https://lnkd.in/eiDtqA2U? ? $LDX #LDX #Lumos #healthcare #pointofcare #diagnostics #AMR #antimicrobialresistance #innovation? #invest

Lumos Diagnostics has been awarded US$2,984,571 from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response. The primary purpose of this funding is to support a planned Clinical Laboratory Improvement Amendments (CLIA)-waiver clinical study and regulatory submission for Lumos’ FebriDx? Bacterial/Non-Bacterial test. Lumos Diagnostics CEO and MD, Doug Ward, commented: “We are honoured to have the opportunity to partner with BARDA on the CLIA waiver study and regulatory submission for FebriDx?. BARDA’s expertise and the associated funding will support our objective of expanding the test's utility - from its current use case in moderate/high complexity labs - to US CLIA-waived point-of-care settings, including physician offices, urgent care clinics, or other outpatient clinics. Should this goal be achieved, FebriDx’s ability to improve antibiotic stewardship will be vastly expanded.” Read the ASX release ?? https://bit.ly/LDX_BARDA $LDX #LDX #Lumos #pointofcare #diagnostics #respiratoryhealth #clinicalstudy #healthcare

?? New Contract ? Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx?, on the MediGroup national contract, making it available to all their members in the United States. FebriDx has been cleared for use in the US by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection. MediGroup is the single largest non-acute care group purchasing organization (GPO) in the United States. Lumos CEO and Managing Director, Doug Ward said: “We are very pleased to see FebriDx? added to MediGroup’s national contract. As a leading group purchasing organization, MediGroup has more than 30,000 members, including a mix of moderately complex labs and CLIA waived locations. This is a key relationship for us as we continue to build out our distribution coverage for FebriDx?.” Read the ASX release ?? https://lnkd.in/gE9cxqvr $LDX #LDX #Lumos #pointofcare #diagnostics #rapidtest #respiratoryhealth #innovation

? Milestone Achieved ? ? Lumos Diagnostics has announced it has successfully completed the first “Phase 2 Milestone” in the development of a new fetal fibronectin (fFN) test for leading women’s health company, Hologic, Inc. Lumos signed two new Agreements with Hologic in January 2024 - an Intellectual Property agreement valued at US$10.0 million and a Development Agreement valued at US$4.7 million. The focus of the Development Agreement is to create a next generation version of Hologic’s on-market fFN diagnostic product for pre-term birth. This includes adapting the test for use on the Lumos proprietary reader platform, with improved connectivity options. Lumos Diagnostics CEO and MD, Doug Ward, commented: “We are proud to achieve this next milestone, which demonstrates the strong progress Lumos and Hologic are making in developing a new fetal fibronectin (fFN) test. We're excited by the results of the work program to date and are pressing ahead with the remainder of the scoped work under Phase 2 of the agreement.” Read the ASX release ?? https://lnkd.in/gngpdYf8 $LDX #LDX #ASX #innovation #medicaldevice #diagnostic #healthcare #innovation #pointofcare

?? AMR in the news More headlines are circulating following the release of a new study published in The Lancet earlier this week, estimating nearly 40 million people could die from antibiotic-resistant infections by 2050. This particular article explores shifting links in AMR-related deaths over nearly three decades, public health improvements, and the all-important need for new antibiotics and improved diagnostics too. 'Given the high variability of AMR burden by location and age, it is important that interventions combine infection prevention, vaccination, minimisation of inappropriate antibiotic use in farming and humans, and research into new antibiotics to mitigate the number of AMR deaths that are forecasted for 2050.' See it here ?? https://lnkd.in/gzJ8BRg5 $LDX #LDX #AMR #superbugs #antibioticresistance #publichealth #Lumos #pointofcare #diagnostics

? Investor Briefings ? Lumos’ management team would like to invite existing and potential investors to attend in-person presentations in Melbourne and Sydney next week. Lumos CEO Doug Ward and CFO Barrie Lambert will visit Melbourne and Sydney to discuss the Company’s full-year results in detail, outline key priorities for the coming year, and provide investors with further business updates. Briefing details: ? MELBOURNE – Tuesday 24 September at 12pm Vault 1 Room, Workspace 365? Level 14, 333 Collins Street, Melbourne VIC? Light lunch, tea and coffee will be available after the presentation. ? SYDNEY – Wednesday 25 September at 12pm Bond Business Centre, Midnight Rambler Room, Workspace 365? Level 4/20 Bond Street, Sydney NSW? Light lunch, tea and coffee will be available after the presentation. To register your interest to attend either briefing, please email Pip Thorn via [email protected] by COB on Friday 20 September 2024. $LDX #LDX #ASX #innovation #medicaldevice #diagnostic #healthcare #innovation #pointofcare